Import from '@/components'

Tymlos (Abaloparatide): How to Safely Stop and What Comes Next

What Tymlos Is and Why the Stop Matters

Abaloparatide is a bone-building drug given as a once-daily 80-mcg subcutaneous injection into the periumbilical area of the abdomen. The FDA approved Tymlos in April 2017 for postmenopausal women with osteoporosis who have a high fracture risk, including those with a prior fragility fracture, multiple risk factors, or who have failed or are intolerant of other osteoporosis therapies.

The way you stop matters as much as how you start. Because abaloparatide works by briefly spiking parathyroid hormone receptor activity to build new bone, the gains it produces are not permanent on their own. Stop the drug without a plan and your skeleton starts losing what it just gained.

How Abaloparatide Works

Abaloparatide is a synthetic analog of parathyroid hormone-related protein (PTHrP). It preferentially binds the PTH1 receptor in its RG conformation, which research published in Science Translational Medicine suggests produces more bone formation relative to bone resorption than teriparatide does, at least in preclinical models. The net effect is a net anabolic window: osteoblast activity is stimulated more than osteoclast activity during the brief daily pulse.

That pulse is the key word. Once you remove the daily signal, the anabolic window closes. Osteoclasts do not suddenly vanish; they resume resorbing bone at rates appropriate for a postmenopausal skeleton.

Who Gets Prescribed Tymlos

The drug is used almost exclusively in postmenopausal women. Approved for up to 24 months of total lifetime use (the same lifetime cap shared with teriparatide), it is typically reserved for women who have T-scores at or below -2.5 combined with at least one fragility fracture, or whose 10-year fracture probability on FRAX is in the high-risk category.

The ACTIVE Trial: What the Evidence Actually Shows

The key ACTIVE trial, published in JAMA in August 2016, enrolled 2,463 postmenopausal women aged 49 to 86 years with osteoporosis. Over 18 months, participants were randomized to abaloparatide 80 mcg daily, teriparatide 20 mcg daily, or placebo.

Fracture Reduction Results

Women on abaloparatide had a 0.58% incidence of new vertebral fractures versus 4.22% in the placebo group, a relative risk reduction of 86%. Nonvertebral fractures fell by 43% compared to placebo. Major osteoporotic fractures were reduced by 70% versus placebo.

These numbers are meaningful. A woman with a prior vertebral fracture has roughly a fivefold higher risk of another vertebral fracture within a year; cutting that risk by 86% translates into real events avoided.

Bone Density Changes

Lumbar spine BMD increased by approximately 11.2% from baseline over 18 months with abaloparatide, versus 7.8% with teriparatide and a small loss with placebo. Total hip BMD rose 3.6% with abaloparatide versus 0.5% with teriparatide.

That 3.1 percentage-point difference at the hip is not trivial. Hip fracture carries the highest morbidity and mortality of any osteoporotic fracture, and improving hip BMD substantially is harder than improving spine BMD.

The ACTIVExtend Extension Study

The ACTIVExtend trial followed women who completed ACTIVE: after the initial phase, participants were transitioned to alendronate 70 mg weekly for 24 months. Women who had received abaloparatide followed by alendronate maintained and extended their BMD gains, achieving lumbar spine BMD increases of 14.4% from original baseline at the end of the extension. This is the direct evidence base for why sequential therapy works and why the transition must happen promptly.

Why You Cannot Simply Stop Tymlos

This is the part most patients are not told clearly enough. Abaloparatide does not leave behind a lasting structural change; it leaves behind a temporarily expanded bone matrix that will shrink back without ongoing antiresorptive support.

Studies with teriparatide, abaloparatide's closest analog, showed that BMD gains at the lumbar spine fell by roughly 3 to 4 percentage points within 12 months of stopping, with no follow-on therapy. Some of that loss occurs within the first three months.

The FDA prescribing information for Tymlos states plainly: "Following abaloparatide, sequential antiresorptive therapy is recommended in order to maintain the bone mineral density gains achieved."

"Stopping an anabolic agent without immediately transitioning to an antiresorptive is like building a house and removing the scaffolding before the mortar cures," says WomanRx clinical reviewer Elena Vasquez, MD. "I see women six months out from their last Tymlos injection who assumed they were done, and their follow-up DXA shows they have lost nearly everything gained."

The Discontinuation Protocol: Step by Step

Stopping Tymlos safely is a three-part process. The timing is not flexible.

Step 1: Know Your Endpoint Before You Start Month 22

The 24-month lifetime limit on abaloparatide is not a soft recommendation. The FDA cap exists because the key trials ran for 18 to 24 months and long-term data beyond that window do not exist. More critically, the rat osteosarcoma signal seen at suprapharmacologic doses in animal studies triggered a boxed warning that drove the lifetime duration restriction. That risk in humans at clinical doses has not been established, but the label limit stands.

At or before month 22, your prescriber should be discussing your antiresorptive follow-on plan. Do not wait for month 24 to have this conversation.

Step 2: Choose Your Sequential Therapy

The two main options are:

Bisphosphonates (alendronate, risedronate, zoledronic acid) Oral alendronate 70 mg once weekly is the most-studied follow-on agent, based on ACTIVExtend. Zoledronic acid 5 mg IV annually is a strong option for women who cannot tolerate oral bisphosphonates or have GI contraindications. Both suppress osteoclast activity and lock in the bone matrix built during anabolic therapy.

Denosumab (Prolia) 60 mg every 6 months Denosumab is a RANK ligand inhibitor that suppresses osteoclast formation. It produces strong antiresorptive effects and is appropriate for women with renal impairment where bisphosphonates are problematic. There is one important caveat: if you choose denosumab as your follow-on and then stop denosumab later without transitioning to a bisphosphonate, you face rebound hypercalcemia and a surge of osteoclast activity that can cause multiple vertebral fractures. Denosumab is not a forever drug either, and your provider needs to have that downstream plan in place before starting it.

Step 3: Timing the Transition

Your last abaloparatide injection and your first antiresorptive dose should be separated by no more than one month. Not two months. Not "whenever your prescription arrives." One month.

If you are transitioning to:

• Weekly alendronate: start the week after your final Tymlos injection
• Monthly ibandronate: start the month following your final injection
• Zoledronic acid infusion: schedule the infusion within 4 weeks of your final injection
• Denosumab 60 mg: schedule the injection within 4 weeks of your final injection

DXA Monitoring Around Discontinuation

Bone density testing at the spine, total hip, and femoral neck should be done at your final Tymlos visit to establish a post-treatment baseline. This is your reference point for monitoring whether your antiresorptive therapy is holding the gains.

A follow-up DXA approximately 12 to 24 months after starting your antiresorptive will tell you whether the transition worked. If BMD is stable or increasing at that point, continue. If you are losing ground despite adherent antiresorptive use, re-evaluation for secondary causes of bone loss or inadequate therapy is warranted.

The Menopause Society's clinical guidelines recommend that DXA intervals not extend beyond two years during active monitoring of women who have transitioned off anabolic therapy.

Life Stage Considerations

Postmenopausal Women

Abaloparatide is approved specifically for this group. After menopause, estrogen withdrawal removes a key brake on osteoclast activity, accelerating bone loss by 1 to 3% per year at the spine in the first several years. Women who completed anabolic therapy and whose ovarian function has been absent for over a decade face a different resorption environment than recently menopausal women. Both need follow-on antiresorptive therapy, but the urgency is arguably higher for longer-postmenopausal women with lower residual bone density.

Early Postmenopause (Within 5 Years of Final Menstrual Period)

Women in early postmenopause prescribed Tymlos for severe osteoporosis (typically due to secondary causes such as long-term glucocorticoids, aromatase inhibitor use, or premature ovarian insufficiency) are a distinct subset. The transition off Tymlos follows the same protocol, but their prescriber should revisit whether the underlying driver of bone loss is being addressed. An aromatase inhibitor that is still on board, for example, continues to suppress estrogen and will blunt any antiresorptive's effectiveness if not accounted for in the plan.

Women on Aromatase Inhibitors for Breast Cancer

Aromatase inhibitor-associated bone loss is a well-established complication of adjuvant breast cancer therapy. Some women are prescribed Tymlos or teriparatide in this context, though this is an off-label use. For these women, the discontinuation conversation is more complex: they may still be on the aromatase inhibitor when they complete Tymlos, meaning the bone-resorbing stimulus continues after the anabolic stimulus stops. Sequential bisphosphonate or denosumab therapy is non-negotiable in this group.

Pregnancy, Lactation, and Contraception

Abaloparatide is contraindicated in pregnancy. This is not a theoretical concern; the drug is not indicated for premenopausal women at all, and there are no adequate human data on use during pregnancy. Animal studies showed fetal toxicity at doses producing exposures similar to the human therapeutic dose.

Women who could become pregnant should not be on this drug. If you are a premenopausal woman with osteoporosis and your provider has discussed Tymlos as an option, ask about alternative anabolic agents and what contraception is required. The FDA label is explicit: Tymlos is for postmenopausal women. Use in premenopausal women is off-label, and reliable contraception would be required for the full treatment course and a defined washout period afterward.

Lactation: There are no data on abaloparatide transfer into human breast milk. Given that the approved indication is postmenopausal women, clinical scenarios involving lactation are rare but not impossible (women with premature ovarian insufficiency or secondary osteoporosis might theoretically be considered). The general principle is that lactation should be avoided during treatment.

Pregnancy category status: Abaloparatide was approved under the modern FDA labeling system (no letter categories), and its label carries the statement that it may cause fetal harm. See the full Prescribing Information for the complete 8.1 and 8.2 sections.

Who Should and Should Not Stop Tymlos

The following framework helps clarify when discontinuation is appropriate versus premature.

Appropriate Reasons to Stop at or Before 24 Months

• You have completed the 24-month lifetime maximum
• You experienced a serious adverse event (osteosarcoma, hypercalcemia, orthostatic hypotension unresponsive to management)
• You developed a condition that makes continued injection therapy impossible or dangerous
• Your fracture risk has been substantially mitigated and you are transitioning by planned protocol

Situations Requiring Special Discussion Before Stopping

• You have been on Tymlos for fewer than 12 months. Stopping before 12 months means you may not have captured full anabolic effect. A prescriber should weigh whether the stopping reason justifies cutting the course short.
• You have a T-score still below -3.0 after treatment. Follow-on therapy choice matters even more in this scenario.
• You are also on glucocorticoids. Prednisone at doses of 5 mg/day or higher is one of the most potent secondary causes of bone loss and will undermine any gains made during anabolic therapy if not addressed alongside the antiresorptive.

Who Should Not Stop Prematurely

Women who are mid-course with significant fracture risk and no adverse events should not stop early simply because of cost or injection fatigue without a full discussion of the risk. A nurse educator or clinical pharmacist session on injection technique and site rotation resolves injection fatigue in many cases. Cost assistance programs from Radius Health exist; your prescriber or pharmacist can access them through the manufacturer's support line.

Side Effects That May Drive Discontinuation Decisions

Some side effects resolve on their own; others are signals to stop.

In the ACTIVE trial, the most common adverse events were:

• Hypercalciuria: 11% with abaloparatide versus 9.6% with teriparatide
• Hypercalcemia: 3.4% versus 6.4% with teriparatide (lower with abaloparatide)
• Orthostatic hypotension: 22.8% versus 17.1% with teriparatide (dizziness after injection is common)
• Nausea: 8.5%
• Palpitations: 10%

Orthostatic hypotension is the side effect most likely to affect adherence. Sitting or lying down for 15 to 30 minutes after each injection reduces this substantially. Injecting at bedtime rather than morning is a clinical trick many prescribers recommend, though the label does not specify a required time of day.

Palpitations warrant monitoring but are generally benign and transient. Any palpitation that persists beyond the first 30 minutes post-injection or is accompanied by chest pain deserves immediate evaluation.

A Note on the Evidence Gap in Women

Women were the population studied in both ACTIVE and ACTIVExtend, which is a relative strength of the abaloparatide evidence base compared to many therapeutic areas. ACTIVE enrolled only postmenopausal women, so the fracture efficacy data are directly applicable to that population.

However, the evidence for optimal sequential therapy duration after abaloparatide is thinner. Most sequential therapy recommendations are extrapolated from post-teriparatide antiresorptive data, not from studies specifically comparing antiresorptive agents head-to-head after abaloparatide. The ACTIVExtend data used alendronate as the single follow-on agent. Whether zoledronic acid, denosumab, or romosozumab produces better long-term outcomes after abaloparatide specifically has not been directly studied in randomized controlled trials.

What to Ask Your Provider Before Your Last Injection

Bring these specific questions to your appointment at month 20 to 22:

1. Which antiresorptive do you recommend for me, and why?
2. On what date will we start it relative to my last Tymlos injection?
3. What does my follow-up DXA schedule look like?
4. If I am on denosumab as follow-on, what is the plan when I eventually stop that?
5. Are any of my current medications (glucocorticoids, aromatase inhibitors, PPIs) affecting my bone density, and are we addressing them?

A prescriber who cannot answer all five questions specifically is not adequately prepared to manage your post-Tymlos care.